JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v6i5.4169ArticlePharmacotherapy of Diabetes Mellitus Type 2: A Review on Various Hypoglycemicshttps://artdesignp.com/journal/JCNR/6/5/10.26689/jcnr.v6i5.4169KhanMuhammad Khalid,U BaigRizwan2022652022-09-26Diabetes is a cosmopolitan medical issue ramifying a large population regardless of ethnicity. Elevated glycemic condition in a patient is explained as diabetes. It can be mainly categorized into Non-Insulin Dependent Diabetes Mellitus (NIDDM) and Insulin Dependent Diabetes Mellitus (IDDM) or Type 1 or Type 2 respectively. Type 1 or IDDM needs insulin therapy exclusively while Type 2 can be controlled via various hypoglycemic agents. Conventional classes contain glitazones, biguanides, sulfonylurea’s and so on, while newly developed drug classes include gliptins or DPP-4 inhibitors, SGLT-2 receptor inhibitors and GLP-1 receptor agonists. The novelty in the anti-hyperglycemic agents have given promising results as compared to the conventional drugs. Insulin cannot be negated as far as its glycemic control is concerned. Furthermore, development of Insulin analogues like detemir, glargine, Lispro have been shown to control glucose levels in the plasma more efficiently.

Olokoba AB, Obateru OA, Olokoba LB, 2012, Type 2 Diabetes Mellitus: A Review of Current Trends. Oman Medical Journal, 27(4): 269–273.

Pranoto A, Novida H, Prajitno JH, et al., 2015, Safety and Efficacy in Early Insulin Initiation as Comprehensive Therapy for Patients with Type 2 Diabetes in Primary Health Care Centers. Acta Med Indones, 479(2): 104–110.

Scheen AJ, 2010, Dipeptidylpeptidase-4 Inhibitors (Gliptins): Focus on Drug-Drug Interactions. Clin Pharmacokinet, 49(9): 573–588. https://www.doi.org/10.2165/11532980-000000000-00000

Kumar BS, A. Ravisankar, Mohan A, et al., 2015, Effect of Oral Hypoglycaemic Agents on Bone Metabolism in Patients with Type 2 Diabetes Mellitus & Occurrence of Osteoporosis. Indian J Med Res, 141(4): 431–437. https://www.doi.org/10.4103/0971-5916.159287

Bazelier MT, Gallagher AM, Van Staa T–P, et al., 2012, Use of Thiazolidinediones and Risk of Osteoporotic Fracture: Disease Or Drugs?. Pharmacoepidemiol Drug Saf, 21(5): 507–514. https://www.doi.org/10.1002/pds.3234

Cao Y, Lam L, 2002, Projections for Insulin Treatment for Diabetics. Drugs Today (Barc), 38(6): 419–427. https://www.doi.org/10.1358/dot.2002.38.6.678349

Chen X-W, He Z–X, Zhou Z–W, et al., 2015, An Update on the Clinical Pharmacology of the Dipeptidyl Peptidase 4 Inhibitor Alogliptin Used for the Treatment of Type 2 Diabetes Mellitus. Clin Exp Pharmacol Physiol, 42(12): 1225–1238. https://www.doi.org/10.1111/1440-1681.12469

Sena CM, Bento CF, Pereira P, et al., 2010, Diabetes Mellitus: New Challenges and Innovative Therapies. EPMA Journal, 1(1): 138–163. https://www.doi.org/10.1007/s13167-010-0010-9

Sola D, Rossi L, Carnevale Schianca GP, Maffioli P, et al., 2013, Sulfonylureas and Their Use in Clinical Practice. Arch Med Sci, 11(4): 840–848. https://www.doi.org/10.5114/aoms.2015.53304

Ferrannini E, DeFronzo RA, 2015, Impact of Glucose-Lowering Drugs on Cardiovascular Disease in Type 2 Diabetes. European Heart Journal, 36(34): 2288–2296. https://www.doi.org/10.1093/eurheartj/ehv239

Yavuz DG, Ozcan S, Deyneli O, 2015, Adherence to Insulin Treatment in Insulin-Naïve Type 2 Diabetic Patients Initiated on Different Insulin Regimens. Patient Preference and Adherence, 2015(9): 1125-1231. https://www.doi.org/10.2147/PPA.S87935

Van Velsen EFS, Lamers J, Blok V, et al., 2014, A Prospective Study of Concomitant GLP-1 Analogue and Insulin Use in Type 2 Diabetes in Clinical Practice. The Netherlands Journal of Medicine, 72(10): 523–527.

Nyenwe EA, Jerkins TS, Umpierrez GE, et al., 2011, Management of Type 2 Diabetes: Evolving Strategies for the Treatment of Patients with Type 2 Diabetes. Metabolism, 60(1): 1–23. https://www.doi.org/10.1016/j.metabol.2010.09.010

Chao EC, 2014, SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clinical Diabetes, 32(1): 4–11. https://www.doi.org/10.2337/diaclin.32.1.4

Filipova EP, Uzunova KH, Vekov TY, 2015, Comparative Analysis of Therapeutic Efficiency and Costs (Experience in Bulgaria) of Oral Antidiabetic Therapies Based on Glitazones and Gliptins. Diabetology & Metabolic Syndrome, 2015(7): 63. https://www.doi.org/10.1186/s13098-015-0059-7

Filippatos TD, Panagiotopoulou TV, Elisaf MS, 2014, Adverse Effects of GLP-1 Receptor Agonists. Rev Diabet Stud, 11(3–4): 202–230. https://www.doi.org/10.1900/RDS.2014.11.202

Vial G, Chauvin M-A, Bendridi N, et al., 2015, Imeglimin Normalizes Glucose Tolerance and Insulin Sensitivity and Improves Mitochondrial Function In Liver of a High-Fat, High-Sucrose Diet Mice Model. Diabetes, 64(6): 2254–2264.

Huri H, Ling D, Ahmad WA, 2015, Association Between Glycemic Control and Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients with Cardiovascular Complications. Drug Design, Development and Therapy, 2015(9): 4735–4749. https://doi.org/10.2147/DDDT.S87294

Huri HZ, Lim PL, Lim SK, 2015, Glycemic Control and Antidiabetic Drugs in Type 2 Diabetes Mellitus Patients with Renal Complications. Drug Design, Development and Therapy, 2015(9): 4355–4371. https://doi.org/10.2147/DDDT.S85676

Chen H-H, Horng M-H, Yeh S-Y, et al., 2015. Glycemic Control with Thiazolidinedione is Associated with Fracture of T2DM Patients. Plos One, 10(8): e0135530. https://doi.org/10.1371/journal.pone.0135530

Mouser JF, 2004, New Drugs for Management of Diabetes: Insulin Analogues, Inhaled Insulin, Pramlintide, and Novel Peptides. Nutrition in Clinical Practice, 19(2): 172–180. https://doi.org/10.1177/0115426504019002172

Rosenstock J, Hanefeld M, Shamanna P, et al., 2014, Beneficial Effects of Once-daily Lixisenatide on Overall and Postprandial Glycemic Levels Without Significant Excess of Hypoglycemia in Type 2 Diabetes Inadequately. J Diabetes and Complications, 28(3): 386–392. https://doi.org/10.1016/j.jdiacomp.2014.01.012

Hermansen K, Mortensen LS, Hermansen M-L, 2008, Combining Insulins with Oral Anti Diabetic Agents: Effect on Hyperglycemic Control, Markers of Cardiovascular Risk and Disease. Vascular Health and Risk Management, 4(3): 561–574. https://doi.org/10.2147/vhrm.s1815

Wu L, Zhu J, Prokop LJ, et al., 2014, Pharmacologic Therapy of Diabetes and Overall Cancer Risk and Mortality: A Meta-Analysis of 265 Studies. Scientific Reports, 5: 10147. https://doi.org/10.1038/srep10147

Bhartia M, Tahrani AA, Barnet AH, 2011, SGLT-2 Inhibitors in Development for Type 2 Diabetes Treatment. The Review of Diabetic Studies 8(3): 348–54. https://doi.org/10.1900/RDS.2011.8.348

Waugh N, Cummins E, Royle P, et al., 2010, Newer Agents for Blood Glucose Control in Type 2 Diabetes: Systematic Review and Economic Evaluation. Health Technology Assessment, 14(36): 1–248. https://doi.org/10.3310/hta14360

Nauck MA, 2014, Update on Developments with Sglt2 Inhibitors in the Management of Type 2 Diabetes. Drug Design, Development and Therapy, 2014(8): 1335-1380. https://doi.org/10.2147/DDDT.S50773

Balfour Jr PC, Rodriguez CJ, Ferdinand KC, 2014, Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents. Curr Hypertens Rep, 16(8): 455. https://doi.org/10.1007/s11906-014-0455-7

Rosenwasser RF, Sultan S, Sutton D, et al., 2013, SGLT-2 Inhibitors and Their Potential in the Treatment of Diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2013(6): 453–467. https://doi.org/10.2147/DMSO.S34416

Ansari RSH, Mady AF, Qutub HO, et al., 2015, Metformin-related Acidosis in a Woman While Performing Haj: A Conservative Approach. Saudi Journal of Kidney Diseases and Transplantation, 26(1): 125–127. https://doi.org/10.4103/1319-2442.148759

Usui R, Yabe D, Kuwata H, et al., 2015, Retrospective Analysis of Safety And Efficacy of Liraglutide Monotherapy and Sulfonylurea-combination Therapy in Japanese Type 2 Diabetes: Association Of Remaining ?-cell Function And Achievement of Hba1c Target One Year After Initiation. Journal of Diabetes and its Complications, 29(8): 1203–1210 https://doi.org/10.1016/j.jdiacomp.2015.07.020

Shaefer Jr CF, Kushner P, Aguilar R, 2015, User’s Guide to Mechanism of Action and Clinical Use of GLP-1 Receptor Agonists. Postgrad Med, 127(8): 818–826. https://doi.org/10.1080/00325481.2015.1090295

Inzucchi SE, Zinman B, Wanner C, et al., 2015, SGLT-2 Inhibitors and Cardiovascular Risk: Proposed Pathways and Review Of Ongoing Outcome Trials. Diabetes & Vascular Disease Research, 12(2): 90–100. https://doi.org/10.1177/1479164114559852

Valsaraj S, Augusti KT, Chemmanam V, et al., 2009, Effects of Insulin, Glimepiride and Combination Therapy of Insulin and Metformin on Blood Sugar and Lipid Profile of NIDDM Patients. Indian Journal of Clinical Biochemistry, 24(2):175–178. https://doi.org/10.1007/s12291-009-0031-0

Fordan S, Raskin P, 2009, Vascular Effects of Rapid-Acting Insulin Analogs in the Diabetic Patient: A Review. Vascular Health and Risk Management, 5(1): 225–231. https://doi.org/10.2147/vhrm.s3402

Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, 2008, Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. International Society for Pharmacoeconomics and Outcomes Research 11(1): 43-51.

Tiwari P, 2015, Recent Trends in Therapeutic Approaches for Diabetes Management: A Comprehensive Update. Journal of Diabetes Research, 2015: 340838. https://doi.org/10.1155/2015/340838

Valla V, 2010, Therapeutics of Diabetesmellitus: Focus on Insulinanalogues and Insulin Pumps. Experimental Diabetes Research, 2010: 178372. https://doi.org/10.1155/2010/178372

Du Y-F, Ou H-Y, Beverly EA, et al., 2014, Achieving Glycemic Control in Elderly Patients with Type 2 Diabetes: A Critical Comparison of Current Options. Clinical Interventions in Aging, 2015(9): 1963–1980. https://doi.org/10.2147/CIA.S53482

Nakamura Y, Hasegawa H, Tsuji M, et al., 2015, Diabetes Therapies in Hemodialysis Patients: Dipeptidase-4 Inhibitors. World Journal of Diabetes, 6(6): 840–849. https://doi.org/10.4239/wjd.v6.i6.840

Nakamura Y, Hasegawa H, Tsuji M, Udaka Y, Mihara M, Shimizu T, Inoue M, Goto Y, Gotoh H, Inagaki M, Oguchi K. Diabetes therapies in hemodialysis patients: Dipeptidase-4 inhibitors. World J Diabetes 2015; 6(6): 840-849 https://doi.org/10.4239/wjd.v6.i6.840

Zhu Z, Shen Z, Lu Y, et al., 2012, Increased Risk of Bladder Cancer with Pioglitazone Therapy in Patients with Diabetes: A Meta-Analysis. Diabetes Research and Clinical Practice, 98(1): 159–163. https://doi.org/10.1016/j.diabres.2012.05.006